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Abstract
Background: Incidence of local relapse after definitive chemoradiation (>59 Gy) for locally advanced non-small-cell
lung cancer (NSCLC) is high, irrespective of high dose radiation applied. Experience with salvage lung resections in
patients with locally relapsed NSCLC after definitive chemoradiation is limited. We present our series of salvage lung
resections for local NSCLC relapse after curative–intent chemoradiation for locally advanced tumor.
Methods: Nine consecutive patients with local tumor recurrence or persistence following definitive chemoradiation
were reviewed. Kaplan-Meier analysis was used to assess patient survival.
Results: All patients received definitive radiation (median dose 66.2 Gy) with concurrent chemotherapy. Tumor
stage prior to chemoradiation was IIIA in 8 patients and IV in 1. In 4 patients tumor invaded the chest wall, in 2 the
spine and in 1 the aorta. Median interval between chemoradiation and salvage resection was 30.2 weeks. Nine
patients underwent 9 resections (6 lobectomies, 1 bilobectomy, 1 pneumonectomy and 1 bi-segmentectomy). One
death occurred on the 12th postoperative day. Median overall survival was 23 months; postoperative 3-year survival
was 47 %. Median progression-free survival was 21 months.
Conclusion: Salvage lung resection for locally recurrent or persisted NSCLC in selected patients with locally
advanced NSCLC following definitive chemoradiation is a worthwhile treatment option.
Background
Since the mid-1990s the definitive chemoradiation therapy
(CRT) has been a commonplace treatment for unresect-
able locally advanced NSCLC, or for resectable tumors in
surgical high-risk patients [1, 2]. A local tumor relapse
rate of up to 35 % can be expected in patients after defini-
tive CRT and remains the dominant cause of death after
the initial therapy [3]. There is no consensus on the effect-
ive local treatment strategy. Treatment options such as
reirradiation, chemotherapy, cryo- and radiofrequency ab-
lation, observation only and/or salvage surgery are applied
[4–6]. The term “salvage surgery” is traditionally used in
the multimodal management of the rectal and anal cancer
as a part of “watch and wait” policy and is usually
indicated for late local recurrence and/or for incomplete
clinical response after neo-adjuvant chemoradiation [7–9].
Recently this term was adopted into the thoracic oncology
and represents a considerable treatment option for local
NSCLC recurrence after stereotactic body radiation in pa-
tients with early stage tumor [9–12]. Moreover, the salvage
lung resection seems to be technically feasible in patients
previously chemoradiated for locally advanced NSCLC
[13–16]. Due to the limited experience, the patient selec-
tion criteria for salvage resections remain unclear. We re-
port on our series of patients who underwent salvage lung
resections for local NSCLC relapse or tumor persistence
following the definitive CRT.
Methods
The medical records of 9 consecutive patients, who under-
went salvage lung resections at single institution between
March 2011 and November 2013, were reviewed. All
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patients were treated for locally advanced NSCLC with a
high dose radiation (>59 Gy) and concurrent platinum-
based chemotherapy with curative intent. Operative selec-
tion criteria were as follow: local recurrence of the tumor
after completion of definitive CRT, presence of the residual
tumor after definitive CRT and cardiorespiratory fitness.
The local recurrence (5 patients) was a new pulmonary le-
sion with high standardized uptake value (SUV). The re-
sidual tumor (4 patients) was defined as persistence of the
tumor in the chest CT with persistently high SUV after
complete definitive CRT. The preoperative diagnostics in-
cluded total body computed tomography (CT) and fluoro-
deoxyglucose positron emission tomography (FDG PET),
cranial MRI and cardiorespiratory function testing. Patient
demographics, NSCLC stage at the time of diagnosis,
pathologic characteristics of the resected tumor, length of
hospital stay, perioperative complications and mortality
were reviewed. The overall survival was calculated from
the time of lung cancer diagnosis. The disease free-survival
was an interval between completion of CRT and detection
of the tumor relapse. The progression-free survival was de-
fined as the interval between the salvage resection and
locoregional or distant recurrence of the tumor. The long-
term survival was a 3-year survival after lung resection.
The statistical data analysis was performed using SPSS
(version 21.0 for Windows; IBM SPSS, Inc., Chicago, IL).
Descriptive statistics were applied for patient characteris-
tics, surgical and oncologic outcome. Survival rates were
calculated using the Kaplan-Meier method and compared
with a long-rank test. Differences were considered to be
statistically significant for p values of <0.05.
Results
The median age at the time of salvage resection was
56.2 years; 8 patients (89 %) were younger than 65. Six
patients (67 %) were male. Detailed pre-CRT patient
characteristics are shown in the Table 1. The median ra-
diation dose applied to the primary tumor was 66.2 Gy
(range 59.4 – 72 Gy). All patients received concurrent
platinum-based chemotherapy in combination with
vinorelbine (in 5 patients) or etoposide (in 4 patients).
Detailed post-treatment characteristics: interval between
CRT and salvage resection, type of resection, tumor stage
and size, percentage of viable cancer cells and postopera-
tive complications are shown in the Table 2. The median
interval between completion of the CRT and salvage sur-
gery was 30.2 weeks (range 12.4 - 165.7 weeks). Eight
lobar or greater resections (5 lobectomies, 1 lobectomy
combined with segmentectomy, 1 bilobectomy, 1 pneu-
monectomy) and 1 bi-segmentectomy (in patient with re-
duced lung function) were performed. All lung resections
were completed by a systematic hilar and mediastinal
lymph node dissection. Seven patients (78 %) required
extended resections (1 chest wall resection, 2 vertebral
column resection and reconstruction, 1 replacement of
descending aorta). The complete tumor resection (R0)
was achieved in all 9 cases and the pathologic examination
demonstrated viable tumor cells in 8 specimens (88 %). In
one patient 27 months after definitive CRT a SUV of 3.3
was detected. But only inactive tumor tissue with exten-
sive necrosis surrounded by fibrosis was found in the
histo-pathologic examination [Fig. 1].
The median duration of the surgery was 3 h 54 min
(range 2 h 02 min - 8 h 26 min). The median blood loss
was 400 ml [Range, 250–550 ml]. One patient developed
an adult respiratory distress syndrome (ARDS) postopera-
tively and required prolonged mechanical ventilation. He
was also re-operated for a post-operative empyema. One
patient died on the 12th day following lobectomy with
partial aortic arch resection, due to multiple organ failure.
The median postoperative length of hospital stay was
20 days (range 9 – 68 days). The median postoperative fol-
low up was 30 months (range 5.7 – 41.2 months). In two
patients a locoregional recurrence 10.3 and 41 months
postoperatively was evident. In other four cases distant me-
tastases occurred. Femoral bone and adrenal gland metasta-
ses were diagnosed in one patient each 6.2 and
18.3 months, respectively. Two patients developed multiple
Table 1 Pre-treatment characteristics
Patients Age (Y)/Gender ECOG Tumor Size (mm) cTNM-Stage Histology Radiotherapy Chemotherapy Reason for def. CRT
1 52/F 0 90 cT4N1M0 Adeno 59.4 Cisplatin/Vorelbine
2 64/M 1 75 cT3N1M0 Squamous 66.6 Cisplatin/Vinorelbine limited lung function
3 63/M 1 49 cT4N1M0 Adeno-squam 72 Carboplatin/Vinorelbine Liver transplantation
4 62/M 2 48 cT3N1M0 Adeno-squam 66 Cisplatin/Etoposide Liver transplantation
5 55/F 0 56 cT4N1M0 Adeno 59.4 Cisplatin/Etoposide
6 37/M 0 37 cT4N0M1 Adeno-squam 66 Carboplatin/Vinorelbine Oligometastasis in
iliacal bone
7 71/M 1 56 cT2N2M0 Adeno 72 Cisplatin/Etoposide limited lung function
8 55/F 0 82 cT4N0M0 Adeno 66.2 Cisplatin/Vinorelbine
9 53/M 0 87 cT4N0M0 Adeno 70.2 Cisplatin/Vinorelbine
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brain metastases 2.5 and 21.9 months postoperatively. Dur-
ing the follow-up interval 3 patients died due to tumor pro-
gression 12, 14 and 22.9 months after the salvage resection,
whereas the patient with adrenal gland metastasis remained
alive and required stereotactic body radiotherapy.
The median overall survival was 63.9 months (range 21.5
– 63.9); the median post-chemoradiation survival was
61.6 months (range 15.3 - 61.6 months). Detailed outcome
is demonstrated in the Table 3. The median postoperative
long-term survival was 23 months (range 10.8 - 38 months)
and the 3 years-survival rate was 47 % [Fig. 2]. The median
progression-free survival was 21 months (range 2.5 -
38 months) and 3-year progressive-free survival rate was
40 %.
Discussion
The rates of local NSCLC recurrence after definitive
CRT are even as high as 85 % at 1 year [17, 18]. Pain,
dyspnoea, haemoptysis and cough are frequent
manifestations [20]. The local NSCLC relapse remains
the leading death cause after the initial therapy [3].
The difficulties in distinguishing between tumor re-
currence and fibrosis or inflammatory changes on the
computed tomography (CT) and FDG-PET are re-
ported [24, 25, 26]. Dense consolidations are typical
for radiation pneumonitis or fibrosis. However, the
tumor re-growth must also be suspected and consid-
ered differential diagnosis [2]. The increased SUVmax
values should require further clearing by CT-guided
or trans-bronchial biopsy. On the other side, the ex-
cessive fibrosis or tumor necrosis has to be expected.
The fine-needle aspiration biopsy provides limited
pathologic information. Therefore, distinguishing be-
tween radiation- and tumor-induced fibrosis may lead
to false-negative findings. In some patients without
tumor recurrence, a moderate FDG hypermetabolic
activity may persist up to 2 years after CRT [22].
Therefore, the optimal treatment strategy, when the
histology is unclear, remains undefined and suspected
recurrence requires at least a comprehensive evalu-
ation [21]. The right time window for the tumor bi-
opsy and for beginning the therapy is crucial. If only
focal tumor nest surrounded by necrotic mass is evi-
dent, the further course of the “remaining tumor” is
unpredictable. Presence of the tumor cell nest must
not indicate the recurrence as those cells may become
necrotic [19, 20]. On the other side, awaiting the
radiological obvious relapse significantly decreases the
overall and the progressive-free survival time [14, 15].
Particularly, in patients with extended relapse invad-
ing the neighbouring structures, the delay in decision
making decreases the chance of the tumor resectabil-
ity. The biological nature of the local NSCLC relapse
is less malignant in comparison to the distant recur-
rence. Therefore the effective local treatment is likely
to be associated with prolonged overall survival and
Table 2 Post-treatment characteristics
Patients Interval between def. RCT
and surgery (month)




1 27.4 upper bilobectomy with chest wall
and Th1-2 resection
T0N0M0 30 0
2 3 extended lobectomy with chest wall T3N0M0 55 60 post-resectional
empyema, ARDS
3 10.8 pneumectomy with aortic arch T4N0M0 70 70 multi-organ failure
4 38.7 S1/2- bisegmentectomy T2aN0M0 50 60
5 7.8 lobectomy with chest wall T3N0M0 50 10
6 6.7 lobectomy with chest wall and T1-3
resection
T4N0M1 10 50
7 6.7 lobectomy T0N2M0 50 10
8 3.5 upper bilobectomy with chest wall T2bN0M0 54 5
9 5.7 lobectomy with chest wall T2bN0M0 62 30
Fig. 1 Histopathologic finding with excessive fibrosis without the
evidence of active tumour cells cuased by definitive chemoradiation
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long-term disease control. In addition, some authors
recommend the salvage resections immediately after
detecting the local recurrence [2].
The choice of a re-treatment strategy for local recur-
rence after the definitive CRT remains challenging. Only
few therapeutic alternatives have been reported. A sys-
tematic literature review regarding the second line
chemotherapy efficacy for relapsed NSCLC shows a
moderate symptom control and response rates for sev-
eral anticancer drugs. The median long-term survival
and progressive-free survival remain under 9 and 6 months
respectively [21]. In addition, Hanna et al. report only a
minimal increase in survival following re-chemotherapy
[22]. The reported median long-term survival after
Table 3 Postoperative outcome




Local recurrence Distant recurrence Tumor relapse Outcome status
1 36.5 36.5 alive tumor free
2 10.2 6.2 femur bone died tumor related
3 died, postoperatively
4 22.9 21.9 diffuse distant metastasis died tumor related
5 18.3 18.3 adrenal gland metastasis alive
6 13 10.3 chest wall ipsilateral dead tumor related
7 44.2 41 lymph node metastasis ipsilateral alive
8 18 alive tumor free
9 14 2.5 multiple brain metastasis dead tumor related
Fig. 2 Overall long-term and progressive-free survival after salvage surgery following definitive chemoradiation
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reirradiation ranges from 5 to 14 months, whereas the 2-
year survival rates and the 2-year progression-free survival
were 27 % and 21 % respectively [17, 20]. Radiation toler-
ance of the lung, esophagus and the spinal cord limit the
radiation dose that could be applied to the recurrent
tumor. Particularly, the myelopathy and the late lung
fibrosis have to be avoided. Jeremic et al. reviewed 11
studies of conventionally fractionated external beam
reirradiation for recurrent NSCLC. The analysis showed
improved overall survival after higher doses compared
with low-dose reirradiation. However, this was associated
with an increased rate of pneumonitis and esophagitis
[3]. Toxicity strongly results from applied total and
cumulative median radiation dose. However, locoregional
and distant tumor control remains disappointing [22]. A
radiofrequency ablation and cryoablation of the local re-
currence is limited by the position of the lesion and the
tumor size. The percutaneous cryoablation is recom-
mended for more central lesions, in proximity to the large
vessels [5]. The radiofrequency ablation is usually per-
formed for lesion smaller than 3 cm. The long-term local
control is dependent on the tumor size and remains, par-
ticularly in cases with lesion greater than 3 cm, unfavour-
able. Due to quick tumor progression frequently repeated
invasive procedures are required [6].
Recently published reports tend to recommend salvage
lung resections as feasible treatment option in absence of
other management strategies for recurrent NSCLC. Due
to limited experience, the patient selection criteria for
“post-radiotherapy” salvage lung surgery are not clearly
defined. Low postoperative mortality and complication
rates despite high-dose stereotactic body radiation support
the idea of salvage surgery for local recurrence in early
stage NSCLC [10, 11]. Four other reports suggest that sal-
vage surgery is associated with prolonged survival in pa-
tients with locally recurrent or persistent tumor after
definitive CRT in locally advanced NSCLC [13–16].
Bauman et al. state that the risk of salvage resection is
proportional to the intensity of fibrotic response after the
high-dose radiation and to the interval between radiation
and resection. However, even in high-risk patients the sal-
vage surgery was technically feasible, with reasonable
results, also when performed after long-time interval [14].
In addition, some authors identified salvage lung surgery
as the best option for patients with local tumor relapse,
resulting in a prolonged survival [13, 23].
Kuzmik et al. reviewed 14 patients who completed de-
finitive chemoradiation with median dose of 57 Gy.
After median interval between chemoradiation and sur-
gery of 33 months [range 0–169 months] local recur-
rence was identified in 54 % of the cases, locoregional in
15 % and distant in 31 %. Viable tumor was found in all
cases (100 %). The median postoperative survival was
9 month with the 2-year survival rate of 49 % [13].
Bauman et al. described 24 patients treated initially with
definitive chemoradiation with a median radiation dose of
63.9 Gy. The median time between radiation and surgery
was 21 weeks. Nineteen patients (78 %) had pathological
proof of viable tumor cells in the resection specimen. The
median survival time for entire cohort was 30 months
with estimated 3-year survival of 47 % [14].
Yang et al. described a cohort of 31 patients with vari-
ous indications for salvage resections. The chemoradia-
tion was performed in 90 % of the cases, with median
radiation dose of 60Gy. The median interval between ra-
diation and surgery was 17.7 weeks. Viable tumor cells
were identified in 19 (61 %) specimens. The median sur-
vival time for entire group was 32.5 months with 3- and
5-year survival rates of 42 % and 31 %, respectively. The
patients with residual disease expected a median survival
time of 20 months. Median survival time in patients
with complete pathologic response was 60 months and
differed statistically significant (p = 0.03) [15].
Casirhagi et al. described an extended salvage resection
in a group of 24 patients. The median time between the
definitive chemoradiation (mean 51 Gy) was 12 weeks and
was therefore close to the time interval for surgical resec-
tion after the induction therapy. Viable tumor was found
in 90 % of the cases. The postoperative 3-years survival
was 42 % [16].
Detailed study characteristics are summarized in the
Table 4.
Our group included only those patients with uncon-
trolled local disease (local relapse or residual tumor
Table 4 Overview to available results for salvage lung surgery after definitive chemoradiation in locally advanced NSCLC




























Bauman 2008 24 60 63.9 29 4.6 20.6 21 30 47 12
Kuzmik 2013 14 33 21 9 49 (2Y)
Casiraghi 2014 43 64 57 21 2.7 12.2 56 42
Yang 2015 31 58 60 40 4 18 16 32.5 42 31 10
Our
study
2015 9 56 66 30 6.7 30.2 78 23 47 21
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following definitive CRT). The median disease-free sur-
vival in our series was similar to the Bauman’s group
(6.7 vs. 5 months). In contrast, Kuzmik et al. performed
salvage resections in patients with tumor recurrence in
the contralateral lung (31 %) and in the other ipsilateral
lobe (15 %). Only 54 % out of 14 salvage lung resections
were performed for local recurrence. The median
disease-free survival for all patients was 33 months
[13]. The ratio of extended salvage resections involv-
ing the neighbouring organs was in our group higher
(21 % by Bauman vs. 21 % by Kuzmik vs. 56 % Yang
and 78 % our group). Remarkable, despite the de-
scribed differences the median long-term survival and
estimated 3-year survival rates in our group were
comparable with other series.
Majority of our patients developed locoregional (25 %)
or distant recurrence (50 %) during the follow-up interval.
Therefore the long-term disease control remains crucial
and interdisciplinary decision making regarding further
treatment is essential. Some important points of agree-
ment are as follow: 1) the salvage lung surgery should be
performed in patients with no other treatment alterna-
tives; 2) the experience in this new field in the thoracic
surgery remains limited; 3) a careful patient selection, par-
ticularly for extended resections, is fundamental.
Our study has a number of limitations. Small number of
salvage resections was performed and the data was col-
lected retrospectively. A control group of patients with local
NSCLC recurrence after definitive CRT managed without
salvage surgery was not available for the comparison.
Salvage extended thoracic surgery may represent a
good therapeutic alternative in well selected cases with
adequate pulmonary reserve and good performance sta-
tus. The individual patient targeted approach is essential
and all alternative treatment options should be discussed
interdisciplinary.
Conclusions
To date, the role of the postradiochemotherapy surgical
lung salvage in patients with local relapse after definitive
chemoradiation for locally advanced NSCLC is poorly
defined. However, salvage resections are technically feas-
ible and are associated with reasonable survival in se-
lected cases. The appropriate long-term tumor control
determines the patient outcome. Therefore, an interdis-
ciplinary consensus and adequate patient selection cri-
teria for salvage surgery are required.
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